Plasma Proteomic Biomarkers Relating to Alzheimer's Disease
Autor: | Liu Shi, Noel J. Buckley, Isabelle Bos, Sebastiaan Engelborghs, Kristel Sleegers, Giovanni B. Frisoni, Anders Wallin, Alberto Lléo, Julius Popp, Pablo Martinez-Lage, Cristina Legido-Quigley, Frederik Barkhof, Henrik Zetterberg, Pieter Jelle Visser, Lars Bertram, Simon Lovestone, Alejo J. Nevado-Holgado |
---|---|
Přispěvatelé: | Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, Amsterdam Neuroscience - Neuroinfection & -inflammation, Amsterdam Neuroscience - Neurodegeneration, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Oncology Fibrinogen-gamma chain Aging medicine.medical_specialty diagnosis Cognitive Neuroscience Neuroscience(all) Alzheimer’s disease (AD) Neurosciences. Biological psychiatry. Neuropsychiatry Disease 03 medical and health sciences blood biomarkers meta-analysis proteomic 0302 clinical medicine Internal medicine medicine Dementia Biology Original Research Medicine(all) Complement component 4 business.industry medicine.disease CTL 030104 developmental biology Meta-analysis Alzheimer's disease (AD) Biomarker (medicine) Human medicine business 030217 neurology & neurosurgery Neuroscience RC321-571 Frontotemporal dementia |
Zdroj: | Frontiers in Aging Neuroscience r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Shi, L, Buckley, N J, Bos, I, Engelborghs, S, Sleegers, K, Frisoni, G B, Wallin, A, Lléo, A, Popp, J, Martinez-Lage, P, Legido-Quigley, C, Barkhof, F, Zetterberg, H, Visser, P J, Bertram, L, Lovestone, S & Nevado-Holgado, A J 2021, ' Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies ', Frontiers in Aging Neuroscience, vol. 13, 712545 . https://doi.org/10.3389/fnagi.2021.712545 Frontiers in aging neuroscience Frontiers in Aging Neuroscience, 13:712545. Frontiers Media S.A. Frontiers in Aging Neuroscience, Vol 13 (2021) Frontiers in aging neuroscience, vol. 13, pp. 712545 |
ISSN: | 1663-4365 |
Popis: | Altres ajuts: Innovative Medicines Initiative Joint Undertaking (EMIF grant agreement no. 115372); Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H); University of Antwerp Research Fund. European Comission. Seventh Framework Programme FP7/2007-2013 and European Comission. Fifth Framework Programme QLRT2001-2455 Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer's disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods: To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results: An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions: The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation. |
Databáze: | OpenAIRE |
Externí odkaz: |